Search / Trial NCT00000574

Ibuprofen in Sepsis Study

Launched by VANDERBILT UNIVERSITY · Oct 27, 1999

Trial Information

Current as of December 26, 2024

Completed

Keywords

ClinConnect Summary

BACKGROUND:

The adult respiratory distress syndrome (ARDS) is a multifactorial disorder most commonly occurring secondary to sepsis syndrome. Sepsis syndrome occurs in 250,000 to 500,000 patients per year with approximately one-third of these developing ARDS and other organ failures. Extensive studies utilizing the sheep endotoxin model of ARDS as well as data from human pilot studies suggest that cyclooxygenase inhibitors (in particular, ibuprofen) would be useful in the prevention and reversal of many of the pathophysiological abnormalities related to sepsis. Animal studies where ibuprof...

Gender

ALL

Eligibility criteria

  • Men and women patients with known or suspected sites of serious infection if core temperature was 38.3 degrees Celsius, heart rate 90 in the absence of beta-blockers, respiratory rate 20 or minute ventilation 10 liters per minute. In addition, one o

Trial Officials

Gordon Bernard

Vanderbilt University

About Vanderbilt University

Vanderbilt University is a prestigious research institution renowned for its commitment to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on collaboration across various disciplines, Vanderbilt leverages its state-of-the-art facilities and a diverse team of experts to conduct rigorous clinical studies. The university is dedicated to improving patient outcomes by exploring novel therapeutic interventions and enhancing understanding of disease mechanisms. Through its robust clinical research infrastructure, Vanderbilt University aims to contribute significantly to the scientific community and the development of effective healthcare solutions.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials